Immunogenicity
INFLUENZA
In Part 1 of the trial, all dose levels of mRNA-1010 (50 µg, 100 µg, and 200 µg) elicited immune responses in participants aged 18–49 years and ≥50 years against all vaccine-matched influenza strains at Day 29 (28 days after vaccination) as measured by HAI (Fig. 